This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Stocks With Recent Price Strength Despite Trade Jitters
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Axsome (AXSM) Catches Eye: Stock Jumps 9.3%
by Zacks Equity Research
Axsome (AXSM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
AnaptysBio (ANAB) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Has Anika Therapeutics (ANIK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ANIK) Outperforming Other Medical Stocks This Year?
Anika (ANIK) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Anika (ANIK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Avid Bioservices (CDMO) Could Be Positioned for a Slump
by Zacks Equity Research
Avid Bioservices (CDMO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Anika Therapeutics (ANIK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 59.52% and 6.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
by Zacks Equity Research
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
Alnylam Presents New Data for RNAi Therapeutic Onpattro
by Zacks Equity Research
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
Epizyme Announces Positive Interim Data on Lead Candidate
by Zacks Equity Research
Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
BioMarin Gets $15M From Pfizer on Talzenna's European Nod
by Zacks Equity Research
BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.
Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
by Zacks Equity Research
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Moving Average Crossover Alert: Anika Therapeutics
by Zacks Equity Research
Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
by Zacks Equity Research
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
by Zacks Equity Research
Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.
Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
Alnylam Completes Enrollment in Phase III Study of Lumasiran
by Zacks Equity Research
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
by Zacks Equity Research
Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.